Background: Clear evidence on the benefit-harm balance and cost effectiveness of
population-based screening for colorectal cancer (CRC) is missing. We aim to systematically …

Background Clear evidence on the benefit-harm balance and cost effectiveness of
population-based screening for colorectal cancer (CRC) is missing. We aim to systematically …

Objectives This study commissioned by the National Committee for Cancer Screening in
Austria systematically evaluates the long-term benefit-harm balance, and cost-effectiveness …

Comparability of cost‐effectiveness of colorectal cancer (CRC) screening strategies is
limited if heterogeneous study data are combined. We analyzed prospective empirical data …

Colorectal cancer (CRC) screening in France is based on a faecal occult blood test every
two years in average risk subjects 50-74 years of age while other endoscopic or non …

Background Colorectal cancer is one of the most common cancers worldwide and is
associated with high mortality when detected at a later stage. There is a paucity of studies …

Colorectal cancer (CRC) screening in France is based on a faecal occult blood test every
two years in average risk subjects 50-74 years of age while other endoscopic or non …

Background Populations differ with respect to their cancer risk and screening preferences,
which may influence the performance of colorectal cancer (CRC) screening programs. This …

Objective To assess the range of strategies analysed in European cost-effectiveness
analyses (CEAs) of colorectal cancer (CRC) screening with respect to the screening …

Individuals with a family history of colorectal cancer (CRC) may benefit from early screening
with colonoscopy or immunologic fecal occult blood testing (iFOBT). We systematically …